Startups
NETRIS Pharma is a unique model of a clinical-stage immuno oncology company integrated within a comprehensive cancer center.
Overview
Employees
11-50
Total raised
$16.65M
Funding Rounds 2
| Date | Series | Amount | Investors |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see |
| Dec 20, 2023 | Series A round | $8.23M |
Mentions in press and media 9
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Oct 19, 2025 | NETRIS Pharma to Present Clinical Results of NP137 in Combination with Immune Checkpoint Inhibitors at ESMO 2025 | Primary efficacy endpoint met in secondary refractory patients The encouraging efficacy and safety results observed in this study strongly support the continued clinical development of NP137” — Dr Jérome Fayette, M.D., Ph.D., Principal Inve... |
| Apr 25, 2025 | NETRIS Pharma Announces Positive Interim Phase II Results for NP137 in combination with anti-PD(L)1 | Confirmation of NP137 Potential to Overcome Resistance to Immune Checkpoint - Clinical Trial Design and Interim Results to be Presented at ASCO and ESMO 2025 We are excited by the potential of NP137 to restore patients sensitivity to immuno... |
| Dec 3, 2024 | NETRIS Pharma Welcomes Eric Falcand as Independent Director to Its Board of Directors | The company’s large pipeline of indications has the potential to make a profound impact on patients’ care in oncology” — Eric FalcandLYON, FRANCE AND GENEVA , SWITZERLAND, December 3, 2024 /EINPresswire.com/ -- NETRIS Pharma, a leading clin... |
| Sep 4, 2024 | NETRIS Pharma appoints Segolène BISOT-LOCARD as Chief Medical Officer | NETRIS Pharma poised to advance into the next phase of clinical development We are thrilled to welcome Dr. Ségolène Bisot-Locard to NETRIS Pharma and look forward to her leadership to drive the late clinical development of our unique netrin... |
| Dec 20, 2023 | France-based Netris Pharma raises EUR 7.5 million in funding | Lyon, France-based clinical-stage biopharmaceutical company developing next-generation molecules targeting cancer resistance, Netris Pharma raised EUR 7.5 million in Series A extension. The company announced the investment on December 19, 2... |
| Dec 19, 2023 | Netris Pharma Raises €7.5M; Extends Series A to €24.4M | Netris Pharma, a Lyon, France-based clinical-stage biopharmaceutical company, raised €7.5M in funding. The round, which brought the total amount to €24.4M, saw participation of new investors including EIC Fund. The company intends to use th... |
| At BIO, French delegation highlights its plans for healthcare and biotech development | At the BIO convention in San Diego June 13-16, France will have a delegation of 87 biotech and medtech companies with events punctuating each day of the conference. The French delegation is also bringing a success story about the country’s ... | |
| NETRIS Pharma | “NETRIS Pharma is a unique model of a clinical-stage immuno oncology company integrated within a comprehensive cancer center.” |
Reviews 0
FAQ about NETRIS PHARMA
How much funding has NETRIS PHARMA raised?
NETRIS PHARMA has raised $16.65M in total across 2 funding rounds.
What funding rounds has NETRIS PHARMA raised?
Parsers VC lists 2 funding rounds of NETRIS PHARMA, among them a Series A round of $8.23M on Dec 20, 2023.
What has the press written about NETRIS PHARMA?
Parsers VC has collected 9 articles mentioning NETRIS PHARMA, among them “NETRIS Pharma to Present Clinical Results of NP137 in Combination with Immune Checkpoint Inhibitors at ESMO 2025” (Oct 19, 2025) and “NETRIS Pharma Announces Positive Interim Phase II Results for NP137 in combination with anti-PD(L)1” (Apr 25, 2025).
Is NETRIS PHARMA still active?
Yes, NETRIS PHARMA is active; its latest activity on Parsers VC dates from May 28, 2026.